GDPR and Healthcare Data in the EU: What UK and Netherlands-Based Health-Tech Startups Must Know Post-Brexit

Brexit did not remove GDPR from UK product roadmaps — it split one familiar rulebook into two. A London-based digital health startup serving patients in Amsterdam, or a Netherlands vendor integrating UK hospital data, now operates under UK GDPR and EU GDPR as separate regimes. The vocabulary looks the same. The supervisory authorities, transfer rules, and enforcement paths do not.

Influrion Solutions is a software development and healthcare IT company that helps founders and compliance officers treat privacy as product architecture, not a privacy-policy PDF. If you are building health-tech in the UK or the Netherlands, this guide covers what actually changed post-Brexit, how special-category health data is handled in both systems, and which engineering choices keep you audit-ready on both sides of the Channel.

What “post-Brexit GDPR” really means for health-tech

Until the end of the transition period, one GDPR applied across the UK and EU. After Brexit:

Topic	UK	EU / Netherlands
Core statute	UK GDPR + Data Protection Act 2018	EU GDPR + national law (NL: AVG + sector rules)
Supervisory authority	ICO	AP (Autoriteit Persoonsgegevens) for NL; lead SA by establishment
Adequacy / transfers	UK–EU transfers rely on adequacy decisions and/or SCCs / UK tools	Transfers to UK treated as third-country unless adequacy covers them
Health data	Special category under UK GDPR Art. 9 analogue	Special category under EU GDPR Art. 9
Breach clock to authority	72 hours (UK GDPR)	72 hours (EU GDPR)

Practical takeaway: “We are GDPR-compliant” is no longer a single claim. Document which regime applies to each processing purpose, each dataset, and each customer contract. Influrion’s rule of thumb: if you cannot name the controller, the legal basis, and the transfer tool for a data path in one sentence, engineering is ahead of compliance — or vice versa.

Special-category health data: the shared hard part

Both UK GDPR and EU GDPR treat health data as special category personal data. That means you need:

1. A lawful basis under Article 6 (or UK equivalent), and
2. A special-category condition under Article 9 (or UK equivalent).

For startups, the common Article 9 routes in health-tech include:

• Explicit consent — workable for consumer wellness and some research apps; fragile for clinical workflows where consent fatigue and power imbalance appear.
• Provision of health or social care — often used when processing is necessary for care delivery under professional secrecy, subject to national conditions.
• Substantial public interest — sometimes used with UK/NL statutory backing (public health, medical research frameworks); do not invent this without counsel.
• Scientific research with appropriate safeguards — useful for secondary use, not a blank cheque for product analytics.

Netherlands nuance: Dutch healthcare practice leans on the AVG plus sectoral norms (including medical professional secrecy and NEN-related security expectations in many buyer RFPs). Hospitals and insurers will ask how your product respects care-context secrecy, not only “we have a cookie banner.”

UK nuance: The Data Protection Act 2018 and sector guidance sit alongside UK GDPR. NHS and private providers often expect DPIAs, DSP Toolkit-style security narratives, and clear subprocessor lists — even when you are not an NHS supplier yet.

Neither regime is satisfied by encryption alone. Encryption is necessary hygiene; lawful basis and purpose limitation are the legal gate.

UK startups serving EU (and Dutch) patients

If you are UK-established and process personal data of people in the EU/EEA in connection with offering goods/services (or monitoring behaviour), EU GDPR can still apply extraterritorially. Post-Brexit, that usually means:

1) Decide establishment vs targeting

• EU establishment (subsidiary, branch, or enough “stable arrangements”) → EU GDPR applies via establishment; appoint roles and DPO logic accordingly.
• No EU establishment but targeting EU users → Art. 3(2) targeting may still pull you into EU GDPR; you may need an EU representative.

2) Fix transfers into the EU and back

Even with UK–EU adequacy decisions in force for periods of time, treat adequacy as revocable policy, not architecture. Design so you can switch to Standard Contractual Clauses (SCCs) plus transfer risk assessment without rewriting your tenancy model.

3) Pick a lead story for Dutch buyers

Netherlands customers care about:

• Where production PHI/health data resides (often EU region preference).
• Who the processor is and whether a DPA (Art. 28) is signed before go-live.
• Whether subprocessors (cloud, email, support, AI hosts) are listed and change-controlled.
• Whether a DPIA exists for high-risk health processing.

Influrion recommends storing EU patient production data in an EU region by default for UK vendors selling into NL, with UK-only tenancy for UK-only customers when commercial isolation helps.

Netherlands startups serving UK patients or UK processors

Dutch vendors are comfortable with EU GDPR — and sometimes underestimate UK divergence.

Checklist for NL → UK:

• Confirm whether UK GDPR applies (offering services to UK individuals / monitoring).
• Use a UK-appropriate transfer tool when sending personal data to the UK if adequacy does not cover your case or you want belt-and-braces (SCCs / UK IDTA patterns as advised by counsel).
• Align contracts: EU Art. 28 DPA language plus UK-specific schedules customers request.
• Do not assume an EU-only DPIA template answers ICO-facing questions about UK special-category conditions and NHS buyer security packs.

If you use UK-based subprocessors (support desks, analytics, model hosts), map each flow: controller (NL clinic) → you (processor) → UK subprocessor. Buyers will ask for that diagram in diligence.

Controllers, processors, and the contracts you actually need

Health-tech startups confuse marketing roles with GDPR roles.

Role	Typical health-tech example	Contract artefact
Controller	Clinic / hospital deciding purposes of patient care data	Your MSA + privacy schedule; customer remains accountable
Joint controllers	Rare but real when two parties jointly determine purposes (e.g. shared research platform)	Joint controller arrangement — draft carefully
Processor	SaaS vendor hosting EHR-adjacent workflows for the clinic	Art. 28 / UK equivalent DPA before personal data flows
Subprocessor	Cloud DB, logging, email, AI inference host	Flow-down + customer notice / approval mechanics

Build implication: your product needs a subprocessor register, region tags on tenants, and a way to pause data flows when a subprocessor changes — not a static PDF updated once a year.

For US PHI overlaps, see our companion pieces on HIPAA vs GDPR and Business Associate Agreements. Those frameworks do not replace GDPR; they stack when you sell both sides of the Atlantic.

DPIAs: when they are not optional

A Data Protection Impact Assessment is expected for high-risk processing — and health data processing at scale almost always qualifies. A usable DPIA for a UK or NL health-tech product answers:

1. What data categories are processed (identifiers, clinical observations, device telemetry, free text)?
2. What are the purposes and legal bases (Art. 6 + Art. 9)?
3. Who are recipients and subprocessors, and where do they process?
4. What are the risks to individuals (confidentiality, incorrect care decisions, re-identification)?
5. What mitigations exist (minimisation, access control, encryption, retention, pseudonymisation, staff training)?
6. What residual risk remains, and who signed off?

Product tip: generate DPIA evidence from your real architecture — data-flow diagrams, retention jobs, RBAC matrices — so the assessment stays true as you ship. Influrion builds privacy controls as features (export, erasure workflows, audit logs) because paper DPIAs fail the first time a supervisor asks for a demo.

Transfers, residency, and architecture choices that age well

Post-Brexit transfer politics will keep moving. Architecture should not.

Prefer these defaults for UK ↔ NL health-tech:

1. Region-pinned tenants — UK data in UK (or agreed) region; EU/NL data in EU region; no silent cross-region replicas for “analytics convenience.”
2. Purpose-separated stores — operational care data ≠ product telemetry ≠ model-training corpora.
3. Pseudonymisation for secondary use — with documented re-identification controls and legal basis for the secondary purpose.
4. Transfer tool abstraction — store which mechanism covers each path (adequacy / SCCs / IDTA) so counsel can update documents without an engineering rewrite.
5. Exit and erasure paths — GDPR data-subject rights must work across regions; “we’ll delete it manually in SQL” is not a rights feature.

Avoid shipping a single global Postgres with mixed UK/EU patient rows and “we’ll filter in the app.” Buyers and auditors both reject that pattern for health data.

A practical 30-day compliance build checklist

Use this as an engineering/compliance sprint backlog — not a lawyer substitute.

Week 1 — Map

• Inventory processing activities (purposes × data categories × systems).
• Assign controller/processor roles per customer type (clinic SaaS vs consumer app).
• Flag every UK ↔ EU data path and current transfer tool.
• List subprocessors with regions and whether health data touches them.

Week 2 — Legal bases and docs

• Document Art. 6 + Art. 9 bases per purpose (UK and EU columns).
• Draft / refresh DPAs, privacy notice, and cookie/consent UX if consent is truly the basis.
• Decide EU representative / UK equivalent needs with counsel if you target the other market without establishment.
• Start DPIA for the highest-risk product surface (usually identifiable clinical data + integrations).

Week 3 — Product controls

• Enforce tenant region pinning and least-privilege RBAC.
• Ship audit logs for access to health records and admin actions.
• Implement export and erasure/restriction workflows that match your retention policy.
• Add subprocessor change notification hooks for customer success / legal.

Week 4 — Prove it

• Run a tabletop breach drill against the 72-hour clock (ICO and/or AP paths).
• Complete DPIA sign-off and file evidence pack (diagrams, policies, access reviews).
• Align sales one-pagers with reality — no “GDPR certified” claims you cannot defend.
• Schedule quarterly review of adequacy/SCC status and subprocessor list.

Buyer questions UK and Dutch customers will ask

Expect these in security questionnaires:

1. Where is production health data stored, and who can access it from which countries?
2. What is your legal basis for processing special-category data in our use case?
3. Can we see your subprocessor list and DPA?
4. How do you handle data-subject access and erasure within statutory timelines?
5. Do you support EU-only (or UK-only) residency for our tenant?
6. What happens to logs and backups after contract end?

If your engineering team cannot demo answers 4–6, pause enterprise sales until they can. Influrion regularly sees deals stall on erasure and residency — not on logo walls.

Common pitfalls (and how to avoid them)

Pitfall	Why it hurts	Better pattern
One privacy policy for “GDPR” worldwide	Misses UK/EU split and NL buyer expectations	Dual-regime register of processing + market-specific notices
Consent banners for clinical SaaS	Wrong tool for care-delivery processing	Care-context Art. 9 condition + contract clarity with the clinic
US cloud defaults without region pin	Transfer and residency objections	Explicit region selection at tenant provision
Training AI on production notes	Secondary purpose without basis / DPIA	Separate corpus, minimisation, documented research basis
“Adequacy forever” architecture	Adequacy can change	SCC-ready contracts + portable residency

FAQ

Does Brexit mean UK health-tech companies can ignore EU GDPR?

No. If you offer services to people in the EU/EEA or monitor their behaviour, EU GDPR can still apply. Separate UK GDPR obligations also apply to UK processing. Plan for both.

Is UK GDPR identical to EU GDPR for health data?

They remain closely aligned on special-category treatment, DPIAs, and breach timing, but supervisory authorities, some national conditions, and transfer tooling differ. Do not copy-paste an EU-only compliance pack for ICO-facing work (or the reverse).

Do Netherlands hospitals require data to stay in the EU?

Many Dutch buyers prefer or require EU residency for health data in practice, even when transfers are legally possible. Architect for EU-region tenancy if you sell seriously into NL healthcare.

Are Standard Contractual Clauses still relevant if adequacy exists?

Yes as a resilience strategy. Adequacy decisions can be amended or challenged. SCCs (and UK transfer tools where applicable) keep commercial and technical options open.

What should we build first: consent UX or access controls?

For B2B clinical products, prioritise identity, RBAC, audit logging, residency, DPAs, and DPIA evidence. Consent UX matters when consent is truly your Art. 9 condition — often consumer or research contexts — not as a substitute for care-context legal analysis.

How Influrion approaches UK ↔ Netherlands health-tech privacy

We treat post-Brexit privacy as a dual-regime design problem: map purposes and roles, pin residency by tenant, make data-subject rights real features, and keep transfer tools replaceable. That is the same engineering discipline we apply to imaging, interoperability, and HIPAA-grade safeguards elsewhere in our healthcare work.

If you are a UK or Netherlands founder scoping a health-tech product that must satisfy UK GDPR and EU GDPR without painting yourself into a residency corner, talk to Influrion Solutions — we can help you turn the checklist above into an architecture and delivery plan.